64
EN | BM-03 Baby breathing monitor
MXA51006
(85956141BM03SJ)
1. Designated health indications
The BM-03 Baby breathing monitor can be used to preventively monitor breathing in
healthy individuals (children). It is recommended to monitor the following indications:
• Whooping cough - the monitor is recommended for 1 month after diagnosis - however,
many children have coughing fi ts for a longer period of time with the risk of vomiting
and the potential threat of inhaling vomit with all the consequences.
• Apnea with bradycardia (slowed heart action) less than 80 beats per minute.
The monitor is recommended for 6 weeks after the symptoms disappear.
• Muscle weakness - can be present in a whole range of muscular and neurological
diseases with varying prognosis. If it is a transient condition, it is recommended to
monitor the infant for 6 weeks after the symptoms disappear.
• Respiratory disorder associated with a decrease in blood oxygen content (desaturation),
the infant may be either pale or greyish/bluish. Monitoring recommended for 6 weeks
after the symptoms disappear.
• Gastroesophageal refl ux (stomach contents returning to the oesophagus, even to the
mouth) can cause breathing problems up to apnoea, slowing of the heart rhythm or
a drop in blood oxygen levels - monitoring recommended for 6 weeks after symptoms
disappear.
• Documented apnoea of more than 20 secs - monitoring for 6 weeks after the apnoea-
related condition ends.
• Infant with an ALTE episode - a condition associated with a combination of apnea,
a change in the colour of the baby‘s skin and mucous membranes, a change in muscle
tone, choking or gagging. Monitoring appropriate for 6 weeks after an ALTE episode.
• Infants with apnoea of prematurity - breathing suddenly stops for at least 20 seconds
or associated with a slowing of the heart rate (below 80 beats per minute) or a decrease
in blood oxygen content in an infant less than 37 weeks’ gestation. Monitoring is
recommended until 43 weeks’ gestation and for a further 6 weeks without the above
clinical symptoms.
• Infants with bradycardia being treated with caffeine, theophylline and similar drugs -
monitoring 6 weeks after treatment ends.
• Infants with chronic lung disease (bronchopulmonary dysplasia), especially those who
need increased oxygen content in the inspired air, CPAP -
Continuous Positive Airway
Pressure
or mechanical ventilation.
• Infants with neurological or metabolic disease affecting respiratory control - the
recommended duration of monitoring depends on the individual severity of the
condition.
• Infants with tracheostomies or anatomical anomalies causing vulnerability of the
developing airway - the need for monitoring depends on the individual disability.
• Previous sibling died of SIDS - if the monitored child has no clinical signs that threaten
respiratory distress, then it is recommended to end monitoring 1 month after the age
of the child who died of SIDS.
• Monitoring an infant in a paediatric inpatient ward after an ALTE episode - after
discharge, home monitoring is recommended depending on the cause of the episode.
12.
BM-03 LIFE SPAN SPECIFICATION
Summary of Contents for BM-03
Page 68: ...BM 03 MXA51006 85956141BM03SJ...
